PA
LAUR icon

PharVision Advisers’s Laureate Education LAUR Stock Holding History

PharVision Advisers’s Portfolio LAUR Stock Details LAUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,775
Closed -$430K – 397
2025
Q4 		$430K Buy
+12,775
New +$394K 0.22% 92

Other funds holding LAUR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
CP
CPV Partners Stamford, Connecticut $224M AUM 77.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

PharVision Advisers's LAUR Position: Q1 2026 in Review

PharVision Advisers sold out of Laureate Education (LAUR) in Q1 2026, closing a stake of 12,775 shares — an estimated $430K sold.

PharVision Advisers first reported a position in LAUR in Q4 2025 and held it in 1 quarter. The position peaked at $430K in Q4 2025. 341 funds tracked by Wall St. Rank hold LAUR as of Q1 2026.

  • PharVision Advisers reported no remaining Laureate Education position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 12,775 Laureate Education shares in Q1 2026, an estimated $430K.
  • PharVision Advisers first reported a position in Laureate Education in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Laureate Education position peaked at $430K in Q4 2025.
  • 341 funds tracked by Wall St. Rank held Laureate Education as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.